Impact Biomedical (IBO) Cash & Current Investments (2022 - 2026)
Impact Biomedical (IBO) posted Cash & Current Investments of $20000.0 for Q1 2026, up 566.67% on a QoQ basis from $3000.0 in Q4 2025, and down 98.48% year-over-year from $1.3 million in Q1 2025.
Impact Biomedical (IBO) Cash & Current Investments (2022 - 2026) Analysis & Trends
Impact Biomedical's Cash & Current Investments history runs 5 years deep, the most recent figure standing at $20000.0 for Q1 2026.
- Quarterly Cash & Current Investments fell 98.48% year-over-year to $20000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20000.0 (down 98.48% YoY) and the FY2025 annual result came in at $3000.0, down 99.85% from the prior year.
- Cash & Current Investments was $20000.0 for Q1 2026 at Impact Biomedical, up from $3000.0 in the prior quarter.
- Across five years, Cash & Current Investments topped out at $2.0 million in Q4 2024 and bottomed at $1000.0 in Q3 2023.
- A 5-year average of $335100.0 and a median of $2500.0 in 2022 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2024 — Cash & Current Investments surged 199800.0% — and 2025, when it slumped 99.85%.
- Impact Biomedical's Cash & Current Investments stood at $2000.0 in 2022, then plunged by 50.0% to $1000.0 in 2023, then jumped by 199800.0% to $2.0 million in 2024, then slumped by 99.85% to $3000.0 in 2025, then jumped by 566.67% to $20000.0 in 2026.
- Business Quant data shows IBO's Cash & Current Investments at $20000.0 in Q1 2026, $3000.0 in Q4 2025, and $1.3 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Impact Biomedical | 46.36 Mn | 46.34 Mn | - | 20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 2.00 Mn |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 3,000.00 |
| Dec 31, 2022 | 2,000.00 |